Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sorrento Therapeutics Inc (NASDAQ:SRNE)

20.78
Delayed Data
As of Jul 31
 +0.39 / +1.91%
Today’s Change
3.10
Today|||52-Week Range
26.80
+106.36%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$740.2M

Company Description

Sorrento Therapeutics, Inc. is a biopharmaceutical company, which engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics that address significant unmet medical needs. Its products and technologies have much broader clinical applications including cancer, autoimmune disorders, metabolic and infectious diseases. Sorrento's clinical pipeline includes Cynviloq which is entering a registrational bio-equivalent study versus albumin-bound paclitaxel and Resiniferatoxin, which is in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. In addition, Sorrento has one of the industry's most diverse fully human antibody libraries (G-MAB) and novel toxins/proprietary conjugation chemistries allowing Sorrento to generate antibody-drug conjugates (ADCs). The Sorrento ADCs have well-defined drug antibody ratios (DAR) in contrast to approved ADCs, which are heterogeneous mixtures with different DARs. These differentiating characteristics may lead to the development of a new of generation ADCs with improved stability and pharmacokinetics while reducing off-target effects. Sorrento Therapeutics was founded by Henry Ji, in 2006 and is headquartered in San Diego, CA.

Contact Information

Sorrento Therapeutics, Inc.
6042 Cornerstone Court West
San Diego California 92121
P:(858) 210-3700
Investor Relations:

Employees

Shareholders

Mutual fund holders8.71%
Individual stakeholders22.23%
Other institutional20.60%

Top Executives

Henry H. JiPresident, Chief Executive Officer & Director
Douglas J. LangstonChief Financial Officer, CAO & VP-Finance
Zhenwei MiaoChief Technology Officer
Mike A. RoyalExecutive VP-Clinical & Regulatory Affairs
George UyChief Commercial Officer & Executive VP